Does Trazodone Cause High Blood Pressure?

Trazodone does not cause high blood pressure. The drug’s pharmacology pushes blood pressure in the opposite direction, and hypotension (abnormally low blood pressure) is one of its best-documented side effects. The concern that most people should have when taking trazodone is not a spike in blood pressure but an unexpected drop, especially when standing up. There are rare scenarios where blood pressure can rise in someone taking trazodone, but they involve drug interactions or unusual metabolic circumstances rather than the drug acting alone.

How Trazodone Affects Blood Vessels

Trazodone is classified as a serotonin antagonist and reuptake inhibitor, but the property most relevant to blood pressure is its blockade of alpha-1 adrenergic receptors. Alpha-1 receptors sit on the smooth muscle cells lining blood vessels. When these receptors are activated by norepinephrine, they cause the vessel walls to contract, which raises blood pressure. Trazodone blocks that signal, so blood vessels stay more relaxed and blood pressure tends to fall.¹

This alpha-1 blocking effect is the same basic mechanism used by prescription blood pressure medications like prazosin and doxazosin. Trazodone was not designed as a blood pressure drug, but its receptor profile overlaps with theirs. The result is a drug that reliably nudges blood pressure downward, particularly when someone shifts from lying or sitting to standing, a moment when the body normally tightens blood vessels to keep blood flowing to the brain.

In isolated rat heart tissue, trazodone had no effect on heart rate at standard experimental concentrations and actually increased coronary blood flow across a wide dose range, consistent with its vessel-relaxing properties.² Unlike some older antidepressants that can speed up the heart or cause rhythm problems, trazodone’s cardiovascular profile is relatively benign outside of its tendency to lower blood pressure.

Orthostatic Hypotension and the Risk of Falls

The most clinically relevant blood pressure issue with trazodone is orthostatic hypotension, the sudden drop in blood pressure that happens when you stand up. Everyone experiences a small dip in blood pressure upon standing, but trazodone amplifies that dip, sometimes dramatically. In a study of older adults already being treated for high blood pressure, those taking trazodone had a systolic blood pressure drop of roughly 16 mmHg immediately upon standing, compared with about 10 mmHg in those not taking the drug. Diastolic pressure dropped by about 11 mmHg versus less than 2 mmHg in the comparison group.³

That extra drop matters because it translates into real-world consequences. In the same study, the rate of syncope (fainting) or falls over 12 months was considerably higher in trazodone users: about 58% experienced at least one episode compared with roughly 21% of those not on the drug. Trazodone was associated with more than double the risk of syncope or falls.⁴ The researchers noted, however, that when dementia was factored into the analysis, the link between trazodone and falls weakened, suggesting that cognitive impairment (which is common among elderly trazodone users prescribed the drug for sleep or agitation) plays a contributing role.

If you are taking trazodone and notice dizziness or lightheadedness when you get up from bed or a chair, that is the alpha-1 blockade at work. Rising slowly, staying hydrated, and avoiding sudden position changes are the standard countermeasures. For people already on blood pressure medication, the combined blood-pressure-lowering effects can be additive, and your doctor may need to adjust your existing antihypertensive doses.

Why Older Adults Are Particularly Vulnerable

Trazodone is widely prescribed off-label for insomnia in older adults, often at low doses of 25 to 100 mg. The logic is understandable: it causes drowsiness, it is not a benzodiazepine, and it does not carry the same addiction profile as traditional sleeping pills. But the blood pressure effects deserve special attention in this population.

Older adults already have less robust reflexes for compensating when blood pressure drops. The baroreceptor response, the body’s rapid-fire system for detecting a blood pressure dip and tightening vessels to correct it, slows down with age. Adding a drug that further relaxes blood vessels on top of an already sluggish compensatory system can create a perfect setup for a fall. Among the geriatric outpatients in the study described above, trazodone users had lower baseline diastolic blood pressure in the office (about 72 mmHg versus 80 mmHg) even when seated, before standing entered the picture.³ The drug was not just amplifying the standing-related drop; it was pulling resting diastolic pressure down as well.

Falls in older adults are not trivial. A hip fracture or head injury from a syncopal episode can be life-altering, and the indirect blood pressure effects of a “mild” sleep aid can be the proximate cause. If you are caring for an older relative who takes trazodone, watching for unsteadiness, especially during nighttime trips to the bathroom (when the drug’s peak sedation and peak blood pressure effect may coincide), is worthwhile.

The mCPP Metabolite and Its Odd Cardiovascular Profile

When the body breaks down trazodone, one of the resulting metabolites is meta-chlorophenylpiperazine, commonly abbreviated mCPP. This compound has its own pharmacological activity, and its relationship with blood pressure is more complicated than trazodone’s.

In animal experiments using pithed rats (animals whose central nervous system has been disabled, isolating peripheral effects), mCPP produced substantial, dose-dependent increases in blood pressure. This pressor effect was blocked by serotonin antagonists but not by alpha-adrenergic blockers, indicating that mCPP was raising blood pressure by activating serotonin receptors on blood vessels rather than through the adrenaline system.⁵ In conscious, freely moving rats, the blood pressure increases were smaller but still present.

However, a separate study tested mCPP in conscious hypertensive rats at doses that clearly activated central serotonin receptors (confirmed by changes in brain serotonin levels and hormone release) and found little effect on blood pressure up to an hour after administration. The researchers noted that their findings were consistent with early human studies that had not demonstrated a blood pressure reduction from mCPP either.⁶

The takeaway is that mCPP has the theoretical capacity to raise blood pressure through direct action on blood vessel serotonin receptors, but in an intact animal (or person) with a functioning central nervous system, central regulatory mechanisms seem to counterbalance any peripheral pressor effects. In practical terms, the blood-pressure-lowering effects of trazodone itself overwhelm whatever mCPP might contribute in the opposite direction. Still, the existence of a metabolite with pressor potential is one reason pharmacologists keep an eye on trazodone’s cardiovascular profile, particularly in people who metabolize the drug unusually slowly and might accumulate more mCPP than average.

Serotonin Syndrome and the Exception That Proves the Rule

There is one genuine scenario in which someone taking trazodone can develop dangerously high blood pressure, and it has nothing to do with trazodone acting alone. Serotonin syndrome occurs when excessive serotonin accumulates in the nervous system, usually because two or more serotonergic drugs are combined. Symptoms range from mild (tremor, agitation, diarrhea) to severe (high fever, seizures, and extreme swings in blood pressure). When neuromuscular hyperexcitability becomes uncontainable, cardiovascular complications can follow, including treatment-resistant high blood pressure.⁷

Trazodone’s weak serotonin reuptake inhibition means it is a lower-risk contributor to serotonin syndrome compared with potent SSRIs or SNRIs. But “lower risk” is not “no risk.” Combining trazodone with an MAOI, a strong SSRI, tramadol, certain migraine medications, or other serotonergic agents can push serotonin levels past the tipping point. In that context, blood pressure can shoot up, sometimes severely. The hypertension in serotonin syndrome is not caused by trazodone per se; it is caused by the serotonin flood triggered by the drug combination. Treating the syndrome (usually by stopping the offending drugs and, in severe cases, using a serotonin antagonist like cyproheptadine) resolves the blood pressure crisis.

If your doctor prescribes trazodone alongside another medication that affects serotonin, this is the interaction to be aware of. The risk is low when trazodone is used as the sole serotonergic agent, but it rises meaningfully with certain combinations.

What Happens in Overdose

Trazodone overdose underscores just how strongly the drug pushes blood pressure downward. A published case report of intentional ingestion of an estimated 2,500 mg of trazodone (many times the therapeutic dose) describes persistent hypotension that required aggressive intravenous fluids, vasopressor medications, and intensive care unit admission to stabilize blood pressure.⁸ The mechanism is the same alpha-1 blockade that causes mild orthostatic hypotension at normal doses, amplified to a dangerous degree. At toxic concentrations, vascular smooth muscle relaxes so thoroughly that the heart cannot maintain adequate perfusion pressure even at maximum output.

Overdose aside, severe hypotension from trazodone at normal doses is uncommon in younger, otherwise healthy adults. The risk gradient runs from minimal in a 30-year-old taking 50 mg for sleep to meaningful in an 80-year-old with existing cardiovascular disease taking multiple blood-pressure-lowering medications.

How Metabolism Varies Between Individuals

Trazodone is metabolized in the liver, primarily by the CYP3A4 enzyme, with CYP2D6 playing a secondary role. People differ in how efficiently these enzymes work, and that variability affects how much trazodone (and its metabolite mCPP) circulates in the blood at any given dose.

A pharmacogenetic study exploring whether CYP2D6 metabolizer status predicted adverse reactions in trazodone-treated patients found a surprising pattern: the occurrence of side effects did not increase neatly with dose. The researchers noted that this was likely because clinicians stopped raising the dose once a patient reported problems, which obscured any dose-response relationship in the data.⁹ In other words, real-world prescribing already adapts to individual tolerance, which makes it harder to detect genetic predictors in observational data.

What this means practically is that two people taking the same dose of trazodone can have quite different blood levels of the drug. A slow metabolizer may experience more pronounced blood pressure drops, more sedation, and potentially more mCPP accumulation. If you find that even a low dose of trazodone makes you dizzy or lightheaded, slow metabolism could be part of the explanation, and your prescriber may be able to adjust accordingly.

Priapism and Peripheral Vascular Effects

One of trazodone’s more unusual side effects is priapism, a prolonged and painful erection unrelated to sexual arousal. Though rare, it is a medical emergency, and it is relevant to the blood pressure discussion because it is driven by the same alpha-1 blocking property.

In penile erectile tissue, alpha-1 receptors normally help maintain the flaccid state by keeping smooth muscle contracted and limiting blood inflow. Trazodone blocks those receptors locally, relaxing the smooth muscle and allowing blood to fill the corpora cavernosa. Animal research confirmed that trazodone, when injected directly into erectile tissue, produced engorgement with increased arterial inflow and venous outflow restriction, mimicking the mechanism of other drugs used therapeutically to induce erections.¹⁰ The alpha-1 antagonist properties of trazodone are the accepted explanation for this effect.

Priapism from trazodone reinforces a broader point about the drug’s vascular personality: it relaxes smooth muscle throughout the body. Different vascular beds express alpha-1 receptors to different degrees, so the clinical effects range from postural dizziness (systemic blood vessels relaxing) to priapism (penile blood vessels relaxing) to nasal congestion (nasal blood vessels dilating). All of these are low-blood-pressure-type effects, not high-blood-pressure-type effects. If someone reports an unusual cardiovascular symptom while on trazodone, the first question is usually whether it fits the pattern of vasodilation, and it almost always does.

When Trazodone Is Prescribed Alongside Blood Pressure Medications

Because trazodone lowers blood pressure through a mechanism that overlaps with alpha-blocker antihypertensives, adding it to an existing blood pressure regimen can produce unexpectedly steep drops. This is most relevant for people who are already on drugs like doxazosin, tamsulosin, or other alpha-blockers (sometimes prescribed for benign prostate enlargement rather than blood pressure). The combination doubles down on alpha-1 receptor blockade in different tissues.

Even when the other blood pressure drug works through a different mechanism, like an ACE inhibitor, a calcium channel blocker, or a diuretic, the net effect of adding trazodone can be an additional few millimeters of mercury off an already low reading. In the elderly study, trazodone users did not differ from non-users on ambulatory or home blood pressure measurements, suggesting that the drug’s blood-pressure-lowering effect is most dramatic in the acute standing moment and may not show up on 24-hour monitoring.⁴ This is important because it means a doctor reviewing your ambulatory blood pressure data might not see a problem even though you are experiencing symptomatic drops every time you stand. Mentioning positional dizziness specifically, rather than waiting for it to show up on monitoring, is the practical step that matters.

For people whose blood pressure runs high and who also need help with sleep or depression, trazodone’s blood-pressure-lowering effect can occasionally be a secondary benefit. Some clinicians view this as a useful feature when selecting among antidepressant options for a hypertensive patient. But relying on trazodone as a blood pressure treatment would be a stretch: its effects are inconsistent, dose-dependent, and concentrated in the orthostatic window rather than sustained throughout the day.